Long-term opioid therapy in chronic noncancer pain: A systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks;Langzeittherapie mit Opioiden bei chronischem nicht-tumorbedingtem Schmerz: Systematische Übersicht und Metaanalyse der Wirksamkeit, Verträglichkeit und Sicherheit in offenen Anschlussstudien über mindestens 26 Wochen

Schmerz

Volumn 29, Issue 1, 2015, Pages 96-108

  Hauser W ^a,b   Bernardy, K ^c   Maier, C ^c  

^a KLINIKUM SAARBRÜCKEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Chronic noncancer pain; Efficacy; Harms; Long term therapy; Open label extension studies; Systematic review

Indexed keywords

BUPRENORPHINE; HYDROMORPHONE; MORPHINE; OPIATE; OXYCODONE; OXYMORPHONE; TAPENTADOL; TRAMADOL; NARCOTIC ANALGESIC AGENT; PHENOL DERIVATIVE;

ANALGESIA; ARTICLE; CHRONIC PAIN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LONG TERM CARE; LOW BACK PAIN; META ANALYSIS; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; OPEN STUDY; PAIN INTENSITY; POLYNEUROPATHY; RADICULAR PAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; DRUG EFFECTS; PAIN MEASUREMENT; TREATMENT OUTCOME;

ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC PAIN; HYDROMORPHONE; LONG-TERM CARE; MORPHINE; OXYCODONE; OXYMORPHONE; PAIN MEASUREMENT; PHENOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRAMADOL; TREATMENT OUTCOME;

EID: 84925466959     PISSN: 0932433X     EISSN: 14322129     Source Type: Journal    
DOI: 10.1007/s00482-014-1452-0     Document Type: Article

References (71)

1. Ballantyne JC, Sullivan MD, Kolodny A (2012) Opioid dependence vs addiction: a distinction without a difference? Arch Intern Med 172:1342–1343
2. Becker WC, Fraenkel L, Kerns RD, Fiellin DA (2013) A research agenda for enhancing appropriate opioid prescribing in primary care. J Gen Intern Med 28(10):1364–1367
3. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101
4. Chaparro LE, Furlan AD, Deshpande A et al (2013) Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev 8:CD004959
5. Chelminski PR, Ives TJ, Felix KM et al (2005) A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Serv Res 5(1):3
6. Chou R, Ballantyne JC, Fanciullo GJ et al (2009) Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 10(2):147–159
7. Edlund MJ, Martin BC, Fan MY et al (2010) Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study. Drug Alcohol Depend 112(1–2):90–98
8. Edlund MJ, Martin BC, Russo JE et al (2013) The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic non-cancer pain: the role of opioid prescription. Clin J Pain (im Druck)
9. Egger M, Smith GD, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
10. Fishbain DA, Cole B, Lewis J et al (2008) What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 9(4):444–459
11. Guilleminault C, Cao M, Yue HJ, Chawla P (2010) Obstructive sleep apnea and chronic opioid use. Lung 188(6):459–468
12. Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383–394
13. Handelsman L, Cochrane KJ, Aronson MJ et al (1987) Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 13(3):293–308
14. Häuser W, Bartram-Wunn E, Bartram C et al (2011) Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors. Pain 152(8):1709–1717
15. Higgins JPT, Green S Cochrane handbook for systematic reviews of intervention. Version 5.1.0. http://handbook.cochrane.org/
16. Højsted J, Ekholm O, Kurita GP et al (2013) Addictive behaviors related to opioid use for chronic pain: a population-based study. Pain 154(12):2677–2683
17. Howe CQ, Sullivan MD (2014) The missing ‚P‘ in pain management: how the current opioid epidemic highlights the need for psychiatric services in chronic pain care. Gen Hosp Psychiatry 36(1):99–104
18. Itz CJ, Geurts JW, Kleef M van, Nelemans P (2013) Clinical course of non-specific low back pain: a systematic review of prospective cohort studies set in primary care. Eur J Pain 17(1):5–15
19. Kipping K, Maier C, Bussemas H, Schwartzer A (2014) Medication compliance in chronic pain. Pain Physician (im Druck)
20. Kissin I (2013) Long-term opioid treatment of chronic nonmalignant pain: unproven efficacy and neglected safety? J Pain Res 6:513–529
21. Lauche R, Klose P, Radbruch L et al (2014) Opioide bei chronischen nicht-tumorbedingten Schmerzen – gibt es Unterschiede? Systematische Übersicht und Metaanalyse der Wirksamkeit, Verträglichkeit und Sicherheit in randomisierten Direktvergleichen von Opioiden über mindestens 4 Wochen. Schmerz. dx.doi.org/10.1007/s00482-014-1432-4
22. Li L, Setoguchi S, Cabral H, Jick S (2013) Opioid use for noncancer pain and risk of fracture in adults: a nested case-control study using the general practice research database. Am J Epidemiol 178(4):559–569
23. Maier C, Schaub C, Willweber-Strumpf A, Zenz M (2005) Long-term efficiency of opioid medication in patients with chronic non-cancer-associated pain. Results of a survey 5 years after onset of medical treatment. Schmerz 19(5):410–417 (German)
24. Maier C, Hildebrandt J, Klinger R et al (2002) Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain—results of a double-blind placebo-controlled trial (MONTAS). Pain 97(3):223–233
25. Manchikanti L, Vallejo R, Manchikanti KN et al (2011) Effectiveness of long-term opioid therapy for chronic non-cancer pain. Pain Physician 14(2):E133–E156
26. Manchikanti L, Helm S II, Fellows B et al (2012) Opioid epidemic in the United States. Pain Physician 15(3 Suppl):ES9–ES38
27. Martin BC, Fan MY, Edlund MJ et al (2011) Long-term chronic opioid therapy discontinuation rates from the TROUP study. J Gen Intern Med 26(12):1450–1457
28. McNicol ED, Midbari A, Eisenberg E (2013) Opioids for neuropathic pain. Cochrane Database Syst Rev 8:CD006146
29. Miller M, Stürmer T, Azrael D et al (2011) Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Geriatr Soc 59(3):430–438
30. Miller K, Yarlas A, Wen W et al (2013) Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. Expert Opin Pharmacother 14(3):269–277
31. Mogri M, Desai H, Webster L et al (2009) Hypoxemia in patients on chronic opiate therapy with and without sleep apnea. Sleep Breath 13(1):49–57
32. Moher D, Liberati A, Teztlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. Ann Intern Med 51:1–7
33. Moore RA, Eccleston C, Derry S et al (2010) „Evidence“ in chronic pain—establishing best practice in the reporting of systematic reviews. Pain 150(3):386–389
34. Moore RA, Derry S, Wiffen PJ (2013) Challenges in design and interpretation of chronic pain trials. Br J Anaesth 111(1):38–45
35. Moore RA (2013) What works for whom? Determining the efficacy and harm of treatments for pain. Pain 154:S77–S86
36. Noble M, Treadwell JR, Tregear SJ et al (2010) Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 1:CD006605
37. Nuckols TK, Anderson L, Popescu I et al (2013) Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med
38. Nüesch E, Rutjes AW, Husni E et al (2009) Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 4:CD003115
39. O’Connor AB, Turk DC, Dworkin RH et al (2013) Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. Pain 154(11):2324–2334
40. Okie S (2010) A flood of opioids, a rising tide of deaths. N Engl J Med 363(21):1981–1985
41. Petzke F, Welsch P, Schaefert R et al (2014) Opioide bei chronischem Kreuzschmerz. Systematische Übersicht und Metaanalyse der Wirksamkeit, Verträglichkeit und Sicherheit in randomisierten, placebokontrollierten Studien über mindestens 4 Wochen. Schmerz. dx.doi.org/10.1007/s00482-014-1449-8
42. Radbruch L, Glaeske G, Grond S et al (2013) Topical review on the abuse and misuse potential of tramadol and tilidine in Germany. Subst Abuse 34(3):313–320
43. Reinecke H, Sorgatz H, German Society for the Study of Pain (DGSS) (2009) S3 guideline LONTS. Long-term administration of opioids for non-tumor pain. Schmerz 23(5):440–447
44. Review Manager (RevMan) [Computerprogramm]. Version 5.2. The Nordic Cochrane Centre, The Cochrane Collaboration, Kopenhagen, 2012
45. Saunders KW, Dunn KM, Merrill JO et al (2010) Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med 25(4):310–315
46. Schaefert R, Welsch P, Petzke F et al (2014) Opioide bei chronischem Arthroseschmerz. Systematische Übersicht und Metaanalyse der Wirksamkeit, Verträglichkeit und Sicherheit in randomisierten, placebokontrollierten Studien über mindestens 4 Wochen. Schmerz. dx.doi.org/10.1007/s00482-014-1451-1
47. Schubert I, Ihle P, Sabatowski R (2013) Increase in opiate prescription in Germany between 2000 and 2010: a study based on insurance data. Dtsch Arztebl Int 110(4):45–51
48. Sjøgren P (2011) Epidemiology of chronic pain and critical issues on opioid use. Pain 152(6):1219–1220
49. Skurtveit S, Furu K, Borchgrevink P et al (2011) To what extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use? Pain 152(7):1555–1561
50. Smith SM, Dart RC, Katz NP et al (2013) Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain 154(11):2287–2296
51. Solomon DH, Rassen JA, Glynn RJ et al (2010) The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med 170(22):1979–1986
52. Sommer C, Welsch P, Schaefert R et al (2014) Opioide bei chronischem neuropathischem Schmerz. Systematische Übersicht und Metaanalyse der Wirksamkeit, Verträglichkeit und Sicherheit in randomisierten, placebokontrollierten Studien über mindestens 4 Wochen. Schmerz. dx.doi.org/10.1007/s00482-014-1455-x
53. Sullivan MD, Howe CQ (2013) Opioid therapy for chronic pain in the United States: promises and perils. Pain 154:S94–S100
54. Von Korff M (2010) Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med 25(4):310–315
55. Walker JM, Farney RJ, Rhondeau SM et al (2007) Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 3(5):455–461
56. Wambach S, Rohr P, Häuser W (2001) Abuse of opioid therapy in somatoform pain disorder. A contribution from a psychosomatic/pain therapist point of view to the discussion of the indication of opioids in nonmalignant pain based on 8 cases. Schmerz 15(4):254–264
57. Watson CP, Watt-Watson J, Chipman M (2010) The long-term safety and efficacy of opioids: a survey of 84 selected patients with intractable chronic noncancer pain. Pain Res Manag 15(4):213–217
58. Weisberg D, Stannard C (2013) Lost in translation? Learning from the opioid epidemic in the USA. Anaesthesia 68(12):1215–1219
59. Zuiderent-Jerak T, Forland F, Macbeth F (2012) Guidelines should reflect all knowledge, not just clinical trials. BMJ 345:e6702
60. Zutler M, Holty JE (2011) Opioids, sleep, and sleep-disordered breathing. Curr Pharm Des 17(15):1443–1449
61. Caldwell JR, Rapoport RJ, Davis JC et al (2002) Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: Results from a randomized, placebo-controlled, doubleblind trial and an open-label extension trial. J Pain Symptom Manage 23:278–291
62. Cloutier C, Taliano J, O’Mahony W et al (2013) Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study. Pain Res Manag 18(2):75–82
63. Gordon A, Callaghan D, Spink D et al (2010) Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther 32(5):844–860
64. Harati Y, Gooch C, Swenson M et al (2000) Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 14(2):65–70
65. Johnson & Johnson. Tapentadol: Clinical Study Report Synopsis CR013567 (KF5503/18). http://clinicaltrials.gov/ct2/show/NCT00487435?term=NCT00487435&rank=1. Zugegriffen: 28. Dezember 2013
66. McIlwain H, Ahdieh H (2005) Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study. Am J Ther 12(2):106–112
67. Portenoy RK, Farrar JT, Backonja MM et al (2007) Long-term use of controlled-release oxycodone for noncancer pain:results of a 3-year registry study. Clin J Pain 23(4):287–299
68. Richarz U, Waechter S, Sabatowski R et al (2013) Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain. Pain Pract 13(1):30–40
69. Roth SH, Fleischmann RM, Burch FX et al (2000) Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 160(6):853–860
70. Sandner-Kiesling A, Leyendecker P, Hopp M et al (2010) Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 64(6):763–774
71. Thorne C, Beaulieu AD, Callaghan DJ et al (2008) A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis. Pain Res Manag 13(2):93–102